A raised reading at a GP surgery, a pharmacy pop-up, or a workplace health check is the start of a diagnostic process, not the end of one. Population-scale blood pressure screening across London is built to catch large numbers of people with a high reading on the day — but a single cuff measurement in a clinical setting is a notoriously unreliable way to decide who actually has hypertension. That’s why NICE guideline NG136 requires a confirmatory step, ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM), before a diagnosis is made. Understanding why that second check exists is central to reading what any screening programme’s numbers really mean.
What Happens After a Raised Clinic Reading
Under NICE NG136, a clinic reading between 140/90 mmHg and 180/120 mmHg does not by itself confirm hypertension. Instead, ABPM is offered to confirm the diagnosis, with HBPM available as an alternative where ABPM is declined or not tolerated. For an ABPM, a person wears a portable cuff connected to a small monitor for a full 24-hour period; the device inflates automatically at set intervals through the day and, less frequently, overnight, building up an average reading across normal daily activity rather than a single moment in a consultation room.
Severe readings are handled differently. Where clinic blood pressure is 180/120 mmHg or higher, NICE requires immediate assessment for target organ damage, with drug treatment started straight away if damage is found rather than waiting on ABPM or HBPM results. If no damage is evident, the clinic reading is simply repeated within 7 days rather than treated as confirmed.
Wearing the Monitor: What the 24 Hours Actually Involves
The practical experience of an ABPM is usually straightforward but takes some getting used to. The cuff sits on the upper arm, connected by a short tube to a compact monitor typically worn on a belt or shoulder strap, and it’s generally kept on under normal clothing for the full day and night. The device inflates automatically at intervals through waking hours, then less often once asleep, so the readings capture an ordinary day rather than the artificially calm few minutes of a consultation. People are usually asked to keep a short log of activity — sleeping, waking, any symptoms — so the clinician reviewing the results can put the numbers in context.
The inconvenience is real but temporary: showering is typically avoided or done carefully to keep the monitor dry, sleep can be disturbed by the cuff inflating overnight, and most people find the first few readings slightly uncomfortable before they stop noticing the cuff altogether. None of this changes the underlying case for using ABPM — a day of minor inconvenience is a reasonable trade for a diagnosis that’s actually accurate, given how much a single clinic reading can be thrown off by the visit itself.
White-Coat Hypertension: When the Cuff Overstates the Risk
White-coat hypertension describes a person whose blood pressure reads high in a clinical setting but is normal everywhere else, once measured by ABPM or HBPM. It’s commonly attributed to the anxiety of the appointment itself rather than a sustained underlying condition. Confirmatory monitoring exists precisely to stop this pattern from resulting in a lifelong diagnosis, and a lifelong medication, that a person may never have needed.
Masked Hypertension: The Harder Problem to Catch
Masked hypertension is the inverse, and arguably the more dangerous of the two: normal readings in the clinic, but elevated blood pressure everywhere else. Because it looks reassuring on a single in-clinic check, it can go undiagnosed through routine screening entirely, even though it carries the same increased risk of cardiovascular events and organ damage as hypertension picked up the conventional way. NICE advises considering ABPM or HBPM specifically for people where a white-coat effect or masked pattern is suspected, not only for those with an outright high reading.
The Numbers That Decide a Diagnosis
| Category | Clinic blood pressure | ABPM daytime average |
|---|---|---|
| Stage 1 hypertension | 140/90 to 159/99 mmHg | 135/85 mmHg or higher |
| Stage 2 hypertension | 160/100 mmHg or higher | 150/95 mmHg or higher |
| Severe hypertension | Systolic 180 mmHg or higher, or diastolic 120 mmHg or higher | Urgent same-day assessment, not an ABPM wait |
Note that the ABPM (or HBPM) thresholds sit lower than the clinic thresholds at every stage. That gap isn’t a rounding difference — it’s a deliberate correction for the fact that readings taken outside a clinical setting tend to run lower even in people who are genuinely hypertensive, so the diagnostic bar is adjusted rather than simply copied across.
What a Second Check Means for Screening at Scale
For a city trying to catch cardiovascular risk early, this two-step pathway matters more than it might first appear. A screening programme that stopped at the first reading would over-diagnose a meaningful share of the people it flags — those with white-coat hypertension — while quietly missing the masked hypertension group who look fine on the day but carry real risk. The confirmatory step is what turns a high-volume first check into something a clinician can actually act on with confidence, whether that means starting treatment, ruling a case out, or referring someone for a longer monitoring period. It’s a slower, less headline-friendly part of the prevention agenda than the screening event itself, but it’s the part that determines whether population-scale detection translates into accurate, individual diagnoses rather than noise.